1. Home
  2. CLSD vs CNTB Comparison

CLSD vs CNTB Comparison

Compare CLSD & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CLSD
  • CNTB
  • Stock Information
  • Founded
  • CLSD 2011
  • CNTB 2012
  • Country
  • CLSD United States
  • CNTB United States
  • Employees
  • CLSD N/A
  • CNTB N/A
  • Industry
  • CLSD Biotechnology: Pharmaceutical Preparations
  • CNTB Biotechnology: Pharmaceutical Preparations
  • Sector
  • CLSD Health Care
  • CNTB Health Care
  • Exchange
  • CLSD Nasdaq
  • CNTB Nasdaq
  • Market Cap
  • CLSD N/A
  • CNTB 68.5M
  • IPO Year
  • CLSD 2016
  • CNTB 2021
  • Fundamental
  • Price
  • CLSD $1.15
  • CNTB $1.24
  • Analyst Decision
  • CLSD Strong Buy
  • CNTB Strong Buy
  • Analyst Count
  • CLSD 6
  • CNTB 1
  • Target Price
  • CLSD $5.17
  • CNTB $8.00
  • AVG Volume (30 Days)
  • CLSD 1.5M
  • CNTB 26.7K
  • Earning Date
  • CLSD 11-11-2024
  • CNTB 09-05-2024
  • Dividend Yield
  • CLSD N/A
  • CNTB N/A
  • EPS Growth
  • CLSD N/A
  • CNTB N/A
  • EPS
  • CLSD N/A
  • CNTB N/A
  • Revenue
  • CLSD $7,524,000.00
  • CNTB $24,116,000.00
  • Revenue This Year
  • CLSD N/A
  • CNTB N/A
  • Revenue Next Year
  • CLSD $438.58
  • CNTB $63.90
  • P/E Ratio
  • CLSD N/A
  • CNTB N/A
  • Revenue Growth
  • CLSD 365.02
  • CNTB N/A
  • 52 Week Low
  • CLSD $0.65
  • CNTB $0.68
  • 52 Week High
  • CLSD $2.12
  • CNTB $2.84
  • Technical
  • Relative Strength Index (RSI)
  • CLSD 44.35
  • CNTB 46.92
  • Support Level
  • CLSD $1.05
  • CNTB $1.22
  • Resistance Level
  • CLSD $1.65
  • CNTB $1.44
  • Average True Range (ATR)
  • CLSD 0.16
  • CNTB 0.13
  • MACD
  • CLSD -0.03
  • CNTB -0.02
  • Stochastic Oscillator
  • CLSD 16.67
  • CNTB 9.68

About CNTB Connect Biopharma Holdings Limited

Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.

Share on Social Networks: